10-Q: Alzamend Neuro Reports Increased Losses, Advances AL001 Trials

Alzamend Neuro, a clinical-stage biopharmaceutical company, reported a significant increase in net loss for the quarter ended July 31, 2025, while advancing its AL001 clinical program and facing a going concern warning.

Summary

• Net loss for the three months ended July 31, 2025, increased to $2.7 million, up 177% from $974,411 in the prior year period.
• Research and development expenses surged by 743% to $1.7 million, primarily due to $1.7 million in clinical trial fees for the Phase IIA brain imaging study of AL001 with Massachusetts General Hospital.
• General and administrative expenses rose 27% to $959,334, driven by higher legal, audit, and marketing fees.
• Cash on hand increased to $5.6 million as of July 31, 2025, from $3.9 million on April 30, 2025, primarily due to $4.0 million in net proceeds from Series C Convertible Preferred Stock issuance.
• The company has an accumulated deficit of $61.2 million and stockholders' equity of $5.3 million as of July 31, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional funding.
• The ALZN002 Phase I/IIA clinical trial for Alzheimer's faced a setback with the termination of the CRO contract by Biorasi, LLC in February 2024, and the company is seeking a replacement.
• Two reverse stock splits were effected: one-for-ten on July 16, 2024, and one-for-nine on May 12, 2025.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including a substantial increase in net loss and a going concern warning. While there is progress with AL001 clinical trials and a recent capital raise, the termination of the ALZN002 CRO contract and identified material weakness in internal controls are notable setbacks, indicating high operational and financial risk.

Positives

• Cash balance increased to $5.6 million as of July 31, 2025, from $3.9 million on April 30, 2025.
• Successfully raised $4.0 million in net proceeds from the issuance of Series C Convertible Preferred Stock during the quarter.
• AL001 Phase IIA clinical trial completed with positive topline data announced in June 2023 and full data in October 2024, identifying a Maximum Tolerated Dose (MTD) of 240 mg TID lithium carbonate equivalent, designed to not require therapeutic drug monitoring (TDM).
• Initiated five new Phase II clinical trials for AL001 (Lithium in Brain studies) in collaboration with Massachusetts General Hospital, with the first healthy subject dosed in May 2025.
• AL001 nonclinical study showed lower plasma lithium levels and consistently higher lithium concentrations in brain tissues compared to lithium carbonate, suggesting an enhanced safety profile and potential for lower doses.
• Stockholders approved the issuance of common stock upon conversion of Series C Preferred Stock and exercise of warrants in excess of the Nasdaq Limit.

Negatives

• Net loss significantly increased by 177% to $2.7 million for the three months ended July 31, 2025, compared to $974,411 in the prior year.
• Research and development expenses surged by 743% to $1.7 million, indicating a higher burn rate.
• Accumulated deficit reached $61.2 million as of July 31, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months due to expected continued losses and insufficient current cash.
• The contract with CRO Biorasi, LLC for the ALZN002 Phase I/IIA clinical trial was terminated in February 2024, requiring the company to seek a replacement CRO.
• A material weakness in internal control over financial reporting was identified due to insufficient accounting department resources, impacting reviews and approvals.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring net losses and insufficient cash to fund operations for the next 12 months.
• Inability to raise additional capital when needed or on favorable terms could force delays, reductions, or elimination of research and development programs and planned clinical trials.
• Future capital requirements are dependent on successful clinical trial enrollment and completion, regulatory approvals, manufacturing agreements, and intellectual property costs.
• The company operates as a single segment, making it vulnerable to risks associated with its specific product candidates and market.
• Material weakness in internal control over financial reporting due to insufficient accounting department resources, which could lead to undetected material misstatements.
• Reliance on third-party licensors (University of South Florida Research Foundation, Inc.) for core intellectual property, with potential for license termination if milestones are not met.
• Clinical trials are inherently risky, and product candidates may not achieve regulatory approval or commercial success.
• The termination of the CRO contract for ALZN002 introduces delays and uncertainty in its clinical development.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future and will require additional capital to fund its development and commercial operations. It plans to seek additional funding through public equity, private equity, and debt financings. The company intends to advance clinical development of AL001 for Alzheimer's, BD, MDD, and PTSD, and ALZN002 for Alzheimer's, while also expanding its pipeline and optimizing product value in major markets. The AL001 Lithium in Brain Phase II clinical trials are expected to provide data to potentially redefine neuropsychiatric, neurodegenerative, and neurological treatment practices by demonstrating equivalent therapeutic benefit at lower lithium doses.

Management Comments

• We expect to continue to incur net losses in the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report.
• These factors create substantial doubt about our ability to continue as a going concern.
• If the Company is unable to obtain funding, it could be required to delay, reduce or eliminate research and development programs and planned clinical trials which could adversely affect the Company's business operations.
• We are currently pursuing the engagement of a replacement CRO [for ALZN002].
• We are implementing measures designed to improve our internal control over financial reporting to remediate material weaknesses, including continuing to formalize our internal control documentation and strengthening supervisory reviews by our management.

Industry Context

Alzamend Neuro operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on neurodegenerative and psychiatric disorders. Its AL001 candidate aims to address the limitations of existing lithium treatments, such as the need for therapeutic drug monitoring (TDM), by offering an enhanced safety profile and improved brain bioavailability. ALZN002 represents an active immunotherapy approach, which could offer a more robust and long-lasting effect compared to passive immunization treatments (e.g., monoclonal antibodies) currently used or in development for Alzheimer's, potentially providing a safer alternative by utilizing autologous immune components.

Comparison to Industry Standards

• AL001 aims to improve upon the "gold standard" lithium treatments for bipolar disorder by mitigating chronic toxicity, poor physicochemical properties, and poor brain bioavailability, potentially eliminating the need for therapeutic drug monitoring (TDM) which is a significant barrier to wider lithium use.
• ALZN002, as an active immunotherapy, is positioned as a potentially safer and more robust alternative to passive immunization treatments, such as monoclonal antibodies (e.g., Aduhelm, Leqembi), which rely on foreign blood products for Alzheimer's treatment.
• The nonclinical study comparing AL001 to lithium carbonate in Alzheimers transgenic mice showed AL001 achieved higher lithium concentrations in brain tissues at lower plasma levels, suggesting a superior therapeutic index compared to conventional lithium salts.

Corporate Governance

Related Party Transactions

• Ault Lending, LLC, a related party due to common management, entered into a securities purchase agreement for Series B Convertible Preferred Stock and warrants.
• The purchase price for 1,220 shares of Series B Convertible Preferred Stock from Ault Lending was paid by the cancellation of $1.15 million of cash advances made by Ault Lending to the company.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future equity raises and past preferred stock conversions. The reverse stock splits aim to maintain share price and NASDAQ compliance but do not change underlying value. The going concern warning poses a substantial risk to investment.
• Employees/Management: Stock-based compensation plans are in place to incentivize, but the material weakness in internal controls highlights operational challenges.
• Customers (future patients): Clinical trial progress with AL001 offers hope for new treatments for Alzheimer's, BD, MDD, and PTSD, but delays in ALZN002 development could impact future treatment options.
• Creditors: The going concern warning and accumulated deficit indicate higher risk for current and potential creditors.
• Licensor (University of South Florida Research Foundation, Inc.): Continues to receive royalties and milestone payments, but license agreements can be terminated if the company fails to meet specified milestones.

Next Steps

• Raise additional capital through public equity, private equity, and debt financings to fund operations and development.
• Continue advancing clinical development of AL001 for Alzheimer's, BD, MDD, and PTSD, including the ongoing Lithium in Brain Phase II clinical trials with Massachusetts General Hospital.
• Engage a replacement CRO for the ALZN002 Phase I/IIA clinical trial to resume its development.
• Expand the pipeline of pharmaceuticals to include additional indications for AL001 and new delivery methods.
• Implement measures to remediate the material weakness in internal control over financial reporting, including increasing accounting department resources.
• Continue efforts to enhance operational, financial, and information management systems and hire additional personnel.

Key Dates

Recommendation

Alzamend Neuro is a high-risk, high-reward clinical-stage biopharmaceutical company. While the progress with AL001, particularly the positive nonclinical data and initiation of new Phase II trials, is encouraging and addresses a significant market need (Alzheimer's, BD, MDD, PTSD), the company faces severe liquidity challenges, evidenced by the 'going concern' warning and recurring net losses. The termination of the CRO contract for ALZN002 introduces significant delays and uncertainty for its other key product candidate. The recent capital raise provides some short-term relief but is unlikely to be sufficient for long-term operations without further dilution. Investors should 'hold' if they have a high-risk tolerance and believe in the long-term potential of AL001, but be aware of the substantial financial and operational risks, including the need for significant future capital raises and the material weakness in internal controls. A 'buy' would be premature given the going concern and ALZN002 setbacks, while a 'sell' might be too aggressive given the potential upside of AL001's clinical progress.

Keywords

Alzamend Neuro, ALZN, Biopharmaceutical, Alzheimer's Disease, Bipolar Disorder, Major Depressive Disorder, Post-Traumatic Stress Disorder, AL001, ALZN002, Clinical Trials, Lithium Ionic Cocrystal, Immunotherapy, SEC Filing, Form 10-Q, Going Concern, Drug Development, Neurodegenerative Diseases, Psychiatric Disorders